Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study.

"Declarations Ethics approval and consent to participatePrior to the inclusion of the first patient, the protocol and other relevant study documents were submitted to the responsible independent ethics committee in accordance with all applicable legislation and regulation. Due to the non-interventional nature of this study, patients were not exposed to any study-specific diagnostic or therapeutic measures; documented voluntary informed consent was a prerequisite for any study-related documentation of data. Consent for publicationAll authors give their consent to publication. Competing interestsThe authors declare that they have had or are having the following economic or personal ties to the pharmaceutical industry, consulting firms, payers, or healthcare providers: A. Straube is or was member of the following advisory boards: Novartis, Lilly, Sanofi, Allergan, TEVA, and speaker or member of speaker boards on behalf of Novartis, Lilly, Sanofi, Allergan, TEVA. He acted as consultant for Sanofi and TEVA, received grant support for research or education from Novartis and acted as an editorial board member for Lilly, Sanofi and Novartis. G. Broessner was or is member of the following advisory boards: Novartis, Lilly, TEVA, Grünenthal, and speaker or member of following speakers boards: Novartis, Lilly, TEVA, Grünenthal; Consultant: Novartis, Lilly, TEVA, Grünenthal; he received grant support for research or education from TEVA. C. Gaul is or was member of the following advisory Boards: Abbvie, Lilly, Novartis Pharma, Hormosan Pharma, Sanofi-Aventis, Perfood, and TEVA, and speaker or member of the following speaker boards: Abbvie, Lilly, Novartis Pharma, Hormosan Pharma, Grünenthal, Sanofi-Aventis, Reckitt-Benckiser and TEVA. He acted as consultant for Weber & Weber, Lundbeck, and Perfood, and served in the following editorial boards: Acta Neurologica Scandinavia, Frontiers in Neurology, and Medizinischer Sachverständiger; Author royalties: Novartis Pharma; furthermore, he is honorary secretary of the German Migraine and Headache Society. J. Hipp and X. Hamann are employees of TEVA GmbH. T. Kraya is or was member of the following advisory Boards: Allergan, and speaker or member of the following speaker boards: Allergan, TEVA, Lilly, Hormosan. L. Neeb was member of the following advisory boards: TEVA, Lilly Novartis and Hormosan and speaker or member of the following speakers’ boards: Lilly, TEVA, Novartis, Abbvie and Hormosan Pharma He received grant support for research from TEVA and Lilly. He served in the editorial boards of Journal of Headache and Pain and Frontiers in Neurology. Competing interests The authors declare that they have had or are having the following economic or personal ties to the pharmaceutical industry, consulting firms, payers, or healthcare providers: A. Straube is or was member of the following advisory boards: Novartis, Lilly, Sanofi, Allergan, TEVA, and speaker or member of speaker boards on behalf of Novartis, Lilly, Sanofi, Allergan, TEVA. He acted as consultant for Sanofi and TEVA, received grant support for research or education from Novartis and acted as an editorial board member for Lilly, Sanofi and Novartis. G. Broessner was or is member of the following advisory boards: Novartis, Lilly, TEVA, Grünenthal, and speaker or member of following speakers boards: Novartis, Lilly, TEVA, Grünenthal; Consultant: Novartis, Lilly, TEVA, Grünenthal; he received grant support for research or education from TEVA. C. Gaul is or was member of the following advisory Boards: Abbvie, Lilly, Novartis Pharma, Hormosan Pharma, Sanofi-Aventis, Perfood, and TEVA, and speaker or member of the following speaker boards: Abbvie, Lilly, Novartis Pharma, Hormosan Pharma, Grünenthal, Sanofi-Aventis, Reckitt-Benckiser and TEVA. He acted as consultant for Weber & Weber, Lundbeck, and Perfood, and served in the following editorial boards: Acta Neurologica Scandinavia, Frontiers in Neurology, and Medizinischer Sachverständiger; Author royalties: Novartis Pharma; furthermore, he is honorary secretary of the German Migraine and Headache Society. J. Hipp and X. Hamann are employees of TEVA GmbH. T. Kraya is or was member of the following advisory Boards: Allergan, and speaker or member of the following speaker boards: Allergan, TEVA, Lilly, Hormosan. L. Neeb was member of the following advisory boards: TEVA, Lilly Novartis and Hormosan and speaker or member of the following speakers’ boards: Lilly, TEVA, Novartis, Abbvie and Hormosan Pharma He received grant support for research from TEVA and Lilly. He served in the editorial boards of Journal of Headache and Pain and Frontiers in Neurology."

"Funding Open Access funding enabled and organized by Projekt DEAL. This study is funded by TEVA GmbH."

"Trial registration Finesse Study is registered on the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (EUPAS44606)."